Detalhe da pesquisa
1.
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Ann Oncol
; 35(1): 77-90, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37879444
2.
Standardizing biomarker testing for Canadian patients with advanced lung cancer.
Curr Oncol
; 25(1): 73-82, 2018 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-29507487
3.
Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study.
Curr Oncol
; 23(6): e589-e597, 2016 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-28050149
4.
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
Curr Oncol
; 23(3): 196-200, 2016 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-27330348
5.
Management of egfr tki-induced dermatologic adverse events.
Curr Oncol
; 22(2): 123-32, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25908911
6.
Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer.
Curr Oncol
; 27(2): e146-e155, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32489263
7.
Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer.
Curr Oncol
; 27(6): 321-329, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33380864
8.
Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.
Curr Oncol
; 16(1): 16-26, 2009 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-19229368
9.
The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement.
Curr Oncol
; 16(1): 27-48, 2009 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-19229369
10.
Canadian Lung Cancer Conference 2019.
Curr Oncol
; 26(4): e578-e580, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31548828
11.
Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.
Curr Oncol
; 26(1): 37-42, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30853796
12.
A network approach to developing immuno-oncology combinations in Canada.
Curr Oncol
; 26(2): 73-79, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31043804
13.
Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.
Curr Oncol
; 26(4): e551-e557, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31548824
14.
Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer.
Curr Oncol
; 15(Suppl 1): S10-5, 2008 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-18231643
15.
Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib.
Curr Oncol
; 15(6): 279-85, 2008 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-19079629
16.
Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer.
Curr Oncol
; 25(Suppl 1): S68-S76, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29910649
17.
Advanced typical and atypical carcinoid tumours of the lung: management recommendations.
Curr Oncol
; 25(Suppl 1): S86-S93, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29910651
18.
Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
Curr Oncol
; 25(5): e385-e390, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30464688
19.
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.
Cancer Treat Rev
; 65: 65-77, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29567557
20.
Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.
Curr Oncol
; 25(2): 163-169, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29719432